by Truveta staff | Feb 26, 2025 | Research
Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity and mortality. While guideline-directed medical therapy (GDMT) has been shown to improve left ventricular ejection fraction (LVEF), real-world data on LVEF recovery and GDMT...
by Truveta Research | Jul 10, 2023 | Research, Research Insights
We explored the demographic characteristics of patients with type 2 diabetes mellitus, heart failure, and chronic kidney disease who received a prescription for empagliflozin (Jardiance) and/or dapagliflozin (Farxiga), two commonly used SGLT2i drugs. We saw...